Abstract
Ninety-two institutionalized elderly subjects were vaccinated with trivalent influenza inactivated vaccine available for the 2011–2012 season, characterized by a prevalent circulation of A(H3N2) influenza viruses (A/Victoria/208-clade) presenting antigenic and genetic patterns different from the A(H3N2) vaccine component (A/Perth/16/2009-clade). Haemagglutination inhibiting (HI) antibody titers were determined in sera collected before, 1 and 6 months after vaccination and patients were considered positive for serological evidence of recent infection if they had a seroconversion on comparing HI titers found in sera collected 1 and 6 months after vaccination. No seroconversions were found against A(H1N1) and B vaccine components. Instead 17 volunteers seroconverted against all or at least some of the different A(H3N2) antigens examined, i.e. the 2011–2012 (A/Perth/16/2009) and the 2012–2013 (A/Victoria/361/2011) vaccine strains and four drifted viruses belonging to the A/Victoria/208-clade circulating in the area were the elderly people were living. The results obtained suggest that influenza infections in the vaccinated volunteers might be due both to a poor match between vaccine and circulating A(H3N2) viruses, since 1 month after vaccination 15 of the 17 volunteers had post-vaccination HI titers considered protective (≥40) against the A(H3N2) vaccine antigen, but not always against the epidemic strains, and to a waning of vaccine induced immune response, since 6 months after vaccination HI titers of non-infected volunteers were found to be decreased as compared with those found 1 month after vaccination.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Broberg E, Snacken R, Aldoch C, Beautè J, Galinska M, Pereyaslov D, Brown C, Penttinen P, on behalf of the WHO European Influenza Surveillance Network (2015) Start of the 2014/15 season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill 20:pii = 21023
Brydak LB, Machala M, Mysliwska J, Mysliwiski A, Trzonkowski P (2003) Immune response to influenza vaccination in an elderly population. J Clin Immunol 23:214–222
Camilloni B, Basileo M, Di Martino A, Donatelli I, Iorio AM (2014) Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immun Ageing 11:10
Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, Guevara M, Moràn J, Irissari F, Arriazu M, Albeniz E, Ezpeleta C, Barricarte A, Promary Health Care Sentinel Network, Network for influenza surveillance in Hospitals of Navarre (2013) Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 18(5): pii = 20388
Cate TR, Couch RB, Parker D, Baxter B (1983) Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza vaccines-1978. Rev Infect Dis 5:737–747
Couch RB (2003) An overview of serum antibody responses to influenza virus antigen. Dev Biol (Basel) 115:25–30
Coudeville L, Bailleux F, Riche R, Megas F, Andre P, Ecochard R (2010) Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 10:18
De Jong JC, Palese AM, Bayer WF, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115:63–73
Harmon MW (1992) Influenza viruses. In: Lenette H (ed) Laboratory diagnosis of viral infections, 2nd edn. Dekker, New York, pp 515–534
Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, García Cenoz M, Castilla J, Pérez E, Gallardo V, Rodriguez C, Vega T, Quinones C, Martínez E, Vanrell JM, Gimenez J, Castrillejo D, Serrano MC, Ramos JM, Larrauri A, and on behalf of the Spanish Influenza Sentinel Surveillance System (2013) Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 13:441
Katz MJ, Hancock K, Xu X (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9:669–683
Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jiménez-Jorge S, Horváth JK, Daviaud I, Guiomar R, Necula G, Bella A, O’Donnell J, Guchowska M, Ciancio BC, Nicoll A, Moren A (2013) Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicenter case–control study. Euro Surveill 18(5):pii = 20390
Masurel N, Laufer J (1984) A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 92:263–276
McElhaney JE (2002) Influenza: a preventable lethal disease. J Gerontol 57A(10):M627–M628
Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, Robertson C, Cottrell S, Smyth B, Zambon M, Moore C, Fleming DM, Watson JM (2013) Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 18(5):pii = 20389
Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Skay DK, Sambhara S (2012) Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 3:68–90
Skowronski DM, Tweed SA, De Serres G (2008) Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 197:490–502
Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW et al (2010) Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 28:3929–3935
Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E (2014) Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccine 2:707–734
World Health Organization (2012) Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season (Internet). World Health Organization, pp 1–16. http://www.who.int/influenza/vaccines/virus/reccomendations/201202_recommendation.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Camilloni, B., Basileo, M., Menculini, G., Tozzi, P., Iorio, A.M. (2015). Partial Protection Induced by 2011–2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People. In: Donelli, G. (eds) Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology(), vol 897. Springer, Cham. https://doi.org/10.1007/5584_2015_5003
Download citation
DOI: https://doi.org/10.1007/5584_2015_5003
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26319-9
Online ISBN: 978-3-319-26320-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)